Posters by gender. by Ignacio García-Espona (21395335)

Subjects:

Correlogram of the relationships among the variables. by Ignacio García-Espona (21395335)

Subjects:

Thematic clouds for lectures. by Ignacio García-Espona (21395335)

Subjects:

Efficiency analysis of various countries [left column: countries ordered according to our national global indicator; central column: countries ordered according to the number of le... by Ignacio García-Espona (21395335)

Subjects:

Comparison cloud indicating the words that appeared most frequently with regard to each type of lecturer (lecturers from the USA, top, blue colour; lecturers not from the USA, bott... by Ignacio García-Espona (21395335)

Subjects:

Global number of lectures and posters (2013-2023). by Ignacio García-Espona (21395335)

Subjects:

Comparison cloud for posters indicating the words that appeared most frequently in each period (2013-2017, top, blue colour; 2018-2023, bottom, red colour). by Ignacio García-Espona (21395335)

Subjects:

Poster ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Kore... by Ignacio García-Espona (21395335)

Subjects:

Lectures by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan, US... by Ignacio García-Espona (21395335)

Subjects:

Lectures by country and year [Top 2-10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan). by Ignacio García-Espona (21395335)

Subjects:

Lecturer ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Ko... by Ignacio García-Espona (21395335)

Subjects:

Sample Data. by Ignacio García-Espona (21395335)

Subjects:

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Supplementary Material for: Decreased Lactococcus lactis and propionic acid in feces of patients with Moyamoya disease: Possible implications of immune dysregulation by figshare admin karger (2628495)

“…The gut microbiota produces short-chain fatty (SCFA) and organic acids, influencing immune regulation and vascular remodeling. We aimed to characterize the gut microbiota in patients with MMD. …”

Variations in the prevalence of OASI in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Trends in the characteristics of women giving birth vaginally in France between 2010 and 2021. by Raphaele Houlbracq (20558509)

Subjects:

Variations in the prevalence of episiotomy in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

pmed.1004501.t001 - Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinat... by Raphaele Houlbracq (20558509)

Subjects:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”